Cargando…

Refueling the Failing Heart: A Case for Sodium-Glucose Cotransporter 2 Inhibition in Cardiac Energy Homeostasis

[Figure: see text]

Detalles Bibliográficos
Autor principal:	Crawford, Peter A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234513/ https://www.ncbi.nlm.nih.gov/pubmed/30456330 http://dx.doi.org/10.1016/j.jacbts.2018.08.002

Ejemplares similares

Rethinking cardiac metabolism: metabolic cycles to refuel and rebuild the failing heart
por: Taegtmeyer, Heinrich, et al.
Publicado: (2014)

Searching in the maze: sodium–glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival
por: Oliveras, Laia, et al.
Publicado: (2023)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
por: Peters, R. J. G.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?
por: McDowell, Kirsty, et al.
Publicado: (2021)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Guiding the failing heart to exercise
por: Gielen, S., et al.
Publicado: (2014)

Nuclear Hmgb1: The Fix for the Failing Heart
por: Raucci, Angela, et al.
Publicado: (2019)

The Mounting Evidence for Permissive Hypercreatinemia in Acute Heart Failure: Adding Sodium Glucose Cotransporter Inhibitors to the List
por: Macedo, Etienne, et al.
Publicado: (2023)

Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
por: Sasaki, Takashi
Publicado: (2018)

An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
por: Seo, Ji A
Publicado: (2019)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function
por: Lee, Hong Kyu
Publicado: (2019)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
por: Brust-Sisti, Lindsay, et al.
Publicado: (2022)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
por: Grubić Rotkvić, Petra, et al.
Publicado: (2020)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
por: Dutka, Mieczysław, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium‐glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
por: Rasalam, Roy, et al.
Publicado: (2021)

Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
por: Afsar, Baris, et al.
Publicado: (2022)

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition
por: Kogot-Levin, Aviram, et al.
Publicado: (2023)

A paradoxical role for alarin in the nervous control of energy homeostasis and thermoregulation: orexigenic but hypermetabolic
por: Roth, Joachim
Publicado: (2014)

Oxygen switches: Refueling for cancer radiotherapy
por: Li, Xianghui, et al.
Publicado: (2023)

Increasing Sodium-Glucose Cotransporter 2 Inhibitor Use in CKD: Perspectives and Presentation of a Clinical Pathway
por: Nishi, Laura, et al.
Publicado: (2022)

Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
por: Naito, Ryo, et al.
Publicado: (2021)

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu
Publicado: (2021)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
por: Cao, Yang, et al.
Publicado: (2022)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

Significance of Microglial Energy Metabolism in Maintaining Brain Homeostasis
por: Bielanin, John P., et al.
Publicado: (2022)

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
por: Philippaert, Koenraad, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
por: Osorio, Horacio, et al.
Publicado: (2012)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
por: Kalra, Sanjay, et al.
Publicado: (2015)

Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
por: Kalra, Sanjay, et al.
Publicado: (2016)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_84fcom0rr8ethqseapqjv7dlsi